July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat moderate-to-severe rheumatoid arthritis patients who have inadequately responded to disease

Read the full 445 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE